These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

810 related articles for article (PubMed ID: 33678096)

  • 1. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
    Aitcheson G; Mahipal A; John BV
    Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
    [No Abstract]   [Full Text] [Related]  

  • 2. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives.
    Rizzo A; Ricci AD; Brandi G
    Expert Opin Investig Drugs; 2021 Apr; 30(4):317-324. PubMed ID: 33054456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Derazantinib: an investigational drug for the treatment of cholangiocarcinoma.
    Braun S; McSheehy P; Litherland K; McKernan P; Forster-Gross N; Bachmann F; El-Shemerly M; Dimova-Dobreva M; Polyakova I; Häckl M; Zhou P; Lane H; Kellenberger L; Engelhardt M
    Expert Opin Investig Drugs; 2021 Nov; 30(11):1071-1080. PubMed ID: 34698609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGFR2 Inhibition in Cholangiocarcinoma.
    Vogel A; Segatto O; Stenzinger A; Saborowski A
    Annu Rev Med; 2023 Jan; 74():293-306. PubMed ID: 36170665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.
    Krook MA; Lenyo A; Wilberding M; Barker H; Dantuono M; Bailey KM; Chen HZ; Reeser JW; Wing MR; Miya J; Samorodnitsky E; Smith AM; Dao T; Martin DM; Ciombor KK; Hays J; Freud AG; Roychowdhury S
    Mol Cancer Ther; 2020 Mar; 19(3):847-857. PubMed ID: 31911531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma.
    Wu Q; Ellis H; Siravegna G; Michel AG; Norden BL; Fece de la Cruz F; Balasooriya ER; Zhen Y; Silveira VS; Che J; Corcoran RB; Bardeesy N
    Clin Cancer Res; 2024 Jan; 30(1):198-208. PubMed ID: 37843855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors.
    Wu T; Jiang X; Zhang X; Wu B; Xu B; Liu X; Zheng L; Wang Y
    Cancer Control; 2021; 28():1073274821989314. PubMed ID: 33618536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma.
    Botrus G; Raman P; Oliver T; Bekaii-Saab T
    Expert Opin Investig Drugs; 2021 Apr; 30(4):309-316. PubMed ID: 33307867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precision approaches for cholangiocarcinoma: progress in clinical trials and beyond.
    Uson Junior PLS; Borad MJ
    Expert Opin Investig Drugs; 2022 Jan; 31(1):125-131. PubMed ID: 34904492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein.
    Wang Y; Ding X; Wang S; Moser CD; Shaleh HM; Mohamed EA; Chaiteerakij R; Allotey LK; Chen G; Miyabe K; McNulty MS; Ndzengue A; Barr Fritcher EG; Knudson RA; Greipp PT; Clark KJ; Torbenson MS; Kipp BR; Zhou J; Barrett MT; Gustafson MP; Alberts SR; Borad MJ; Roberts LR
    Cancer Lett; 2016 Sep; 380(1):163-73. PubMed ID: 27216979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting FGFR inhibition in cholangiocarcinoma.
    Goyal L; Kongpetch S; Crolley VE; Bridgewater J
    Cancer Treat Rev; 2021 Apr; 95():102170. PubMed ID: 33735689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.
    DiPeri TP; Zhao M; Evans KW; Varadarajan K; Moss T; Scott S; Kahle MP; Byrnes CC; Chen H; Lee SS; Halim AB; Hirai H; Wacheck V; Kwong LN; Rodon J; Javle M; Meric-Bernstam F
    J Hepatol; 2024 Feb; 80(2):322-334. PubMed ID: 37972659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.
    King G; Javle M
    Curr Oncol Rep; 2021 Jul; 23(9):108. PubMed ID: 34269915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma.
    Rizzo A; Ricci AD; Brandi G
    Cancer Treat Res Commun; 2021; 27():100337. PubMed ID: 33611090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
    Borad MJ; Champion MD; Egan JB; Liang WS; Fonseca R; Bryce AH; McCullough AE; Barrett MT; Hunt K; Patel MD; Young SW; Collins JM; Silva AC; Condjella RM; Block M; McWilliams RR; Lazaridis KN; Klee EW; Bible KC; Harris P; Oliver GR; Bhavsar JD; Nair AA; Middha S; Asmann Y; Kocher JP; Schahl K; Kipp BR; Barr Fritcher EG; Baker A; Aldrich J; Kurdoglu A; Izatt T; Christoforides A; Cherni I; Nasser S; Reiman R; Phillips L; McDonald J; Adkins J; Mastrian SD; Placek P; Watanabe AT; Lobello J; Han H; Von Hoff D; Craig DW; Stewart AK; Carpten JD
    PLoS Genet; 2014 Feb; 10(2):e1004135. PubMed ID: 24550739
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Cleary JM; Raghavan S; Wu Q; Li YY; Spurr LF; Gupta HV; Rubinson DA; Fetter IJ; Hornick JL; Nowak JA; Siravegna G; Goyal L; Shi L; Brais LK; Loftus M; Shinagare AB; Abrams TA; Clancy TE; Wang J; Patel AK; Brichory F; Vaslin Chessex A; Sullivan RJ; Keller RB; Denning S; Hill ER; Shapiro GI; Pokorska-Bocci A; Zanna C; Ng K; Schrag D; Jänne PA; Hahn WC; Cherniack AD; Corcoran RB; Meyerson M; Daina A; Zoete V; Bardeesy N; Wolpin BM
    Cancer Discov; 2021 Oct; 11(10):2488-2505. PubMed ID: 33926920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyclonal Secondary
    Goyal L; Saha SK; Liu LY; Siravegna G; Leshchiner I; Ahronian LG; Lennerz JK; Vu P; Deshpande V; Kambadakone A; Mussolin B; Reyes S; Henderson L; Sun JE; Van Seventer EE; Gurski JM; Baltschukat S; Schacher-Engstler B; Barys L; Stamm C; Furet P; Ryan DP; Stone JR; Iafrate AJ; Getz G; Porta DG; Tiedt R; Bardelli A; Juric D; Corcoran RB; Bardeesy N; Zhu AX
    Cancer Discov; 2017 Mar; 7(3):252-263. PubMed ID: 28034880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma.
    Saborowski A; Vogel A; Segatto O
    Trends Cancer; 2022 Feb; 8(2):83-86. PubMed ID: 34840108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy.
    Brown ZJ; Ruff SM; Pawlik TM
    Expert Rev Anticancer Ther; 2023 Mar; 23(3):257-264. PubMed ID: 36744395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Narrative review: current management and novel targeted therapies in intrahepatic cholangiocarcinoma.
    Bath NM; Pawlik TM
    Chin Clin Oncol; 2023 Feb; 12(1):5. PubMed ID: 36922354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.